Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 9/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.35 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.35 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 1/20 | 0.35 |
| ▸ | RXRG | P48443 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10088869 | 0.93 | ALOX5 (0.37) | ALOX5S1PR1MRGPRX4S1PR4S1PR5 | |
| SCHEMBL10089079 | 0.92 | ALOX5 (0.37) | ALOX5S1PR1MRGPRX4S1PR4S1PR5 | |
| SCHEMBL10088854 | 0.92 | S1PR1 (0.37) | ALOX5S1PR1MRGPRX4S1PR4S1PR5 | |
| SCHEMBL10088878 | 0.91 | S1PR1 (0.38) | ALOX5S1PR1MRGPRX4S1PR4S1PR5 | |
| SCHEMBL10088831 | 0.91 | S1PR1 (0.45) | ALOX5S1PR1MRGPRX4S1PR4S1PR5 | |
| SCHEMBL10089046 | 0.88 | ALOX5 (0.38) | ALOX5S1PR1MRGPRX4S1PR4S1PR5 | |
| SCHEMBL10088861 | 0.86 | S1PR1 (0.46) | ALOX5S1PR1S1PR4S1PR5 | |
| SCHEMBL2327510 | 0.84 | S1PR1 (0.43) | ALOX5S1PR1S1PR4S1PR5 | |
| Hydrochloric Acid SCHEMBL17530055 | 0.84 | S1PR1 (0.43) | ALOX5S1PR1S1PR4S1PR5 | |
| SCHEMBL17510080 | 0.83 | S1PR1 (0.40) | ALOX5S1PR1S1PR4S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178735-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | ASTELLAS PHARMA INC. (JP) | 2012-07-12 | — | — | US | disclosed |
| US-8193378-B2 | 2H-chromene compound and derivative thereof | ASTELLAS PHARMA INC. (JP) | 2012-06-05 | — | — | US | disclosed |
| US-20110230463-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-09-22 | — | — | US | disclosed |
| WO-2010064707-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | アステラス製薬株式会社 (JP) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230463-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | S1PR1, S1PR2, CCR1 | ALOX5 257/4885S1PR1 1/4885MRGPRX4 319/4885 |
| US-20120178735-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | S1PR1, S1PR2, S1PR4 | ALOX5 377/4885S1PR1 1/4885MRGPRX4 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.